Sensei is a biopharmaceutical company engaged in the discovery, development and delivery of next-generation immunotherapies for the treatment of cancer. The company is developing a pipeline of medicines designed to fulfill the substantial potential of the immune system to defeat cancer and other diseases. It has developed two unique approaches. The first approach is Sensei’s proprietary ImmunoPhage™ platform, which leverages the self-adjuvanted and highly immunogenic properties of engineered bacteriophage. This platform allows Sensei to develop novel therapeutics that target key mechanisms of checkpoint resistance to induce a robust, focused and coordinated immune response. The second approach is the company’s monoclonal antibody and nanobody platform, which is comprised of unique human monoclonal antibodies and alpaca-derived nanobodies that are selectively active only in the tumor microenvironment.
Sensei is developing a library of ImmunoPhage targeting multiple tumor-associated antigens, also known as PhortressTM, utilizing its proprietary platform and GMP manufacturing facility to treat patients using a personalized, yet off the shelf cocktail approach.
Sensei’s ImmunoPhage programs include SNS-401-NG, a preclinical candidate for the treatment of Merkel cell carcinoma and a human monoclonal antibody program targeting the immune checkpoint VISTA, or V-set immunoglobulin domain suppressor of T cell activation.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it will present preclinical data for its anti-VISTA (V-domain Ig suppressor of T cell
Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program
- Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model – - Company plans to select a lead SNS-VISTA candidate and initiate IND-enabling studies by year-end 2021 -
BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointment of Kristian Humer, former managing director of Banking, Capital